Recent developments highlight progress in clinical development and financial position, including completion of GMP pilot, patient case study publication, and cash position at quarter-end.

• Curanex completed a GMP pilot for Phyto-N and targets IND submission for ulcerative colitis [N3].
• The company showcased a patient case study highlighting the potential of Phyto-N, which was positively received [N2].
• Curanex ended Q1 2026 with $4 million in cash and announced plans for IND submission for Phyto-N in treating ulcerative colitis [N1].

The bull case for Curanex centers on successful clinical development and regulatory approval of Phyto-N as a novel botanical drug for ulcerative colitis, addressing an unmet medical need. Completion of GMP pilot manufacturing and planned IND submission mark important milestones. Positive patient case studies and ongoing research may support the drug's potential efficacy. If the company secures robust patent protection and manages to finance its development plan, it could establish a foothold in a niche botanical drug market with limited competition. Strong liquidity ratios as of mid-2026 provide some runway for near-term development activities.

The bear case involves the high risks inherent in early-stage pharmaceutical development, including potential failure in clinical trials, delays in regulatory approvals, and inability to secure or maintain effective patent protection. The company has no commercial products or revenues and depends on raising substantial additional capital, which may not be available on favorable terms. Reliance on third-party manufacturers and collaborators introduces operational risks. Competitive pressures and intellectual property disputes could further challenge the company's prospects. Failure to manage growth or secure financing could lead to curtailment or discontinuation of operations.

Curanex's moat is primarily based on its proprietary botanical drug candidate Phyto-N and associated intellectual property rights. The company has filed an international PCT application to secure broader patent protection for Phyto-N, which is critical given the competitive pharmaceutical landscape and challenges in protecting botanical drug formulations. The complexity of botanical drug development, including standardization and regulatory hurdles, may provide some differentiation. However, the company is in early development stages with no commercial products, and its competitive position depends heavily on successful clinical development, regulatory approvals, and effective patent protection.

• Limited Operating History and No Commercial Products: Curanex has a limited operating history and no revenue-generating products, increasing uncertainty about future prospects and success.
• Significant Capital Requirements: The company estimates over $150 million needed to complete development and commercialization of Phyto-N, requiring substantial additional financing.
• Clinical Trial Risks: Clinical trials have a high risk of failure or delays, which could impair commercial prospects and require operational reductions.
• Intellectual Property Challenges: Patent protection for Phyto-N is uncertain; failure to obtain or maintain patents could diminish competitive advantage and business viability.
• Dependence on Third Parties: Reliance on third-party manufacturers and collaborators poses risks of supply disruptions, delays, and operational challenges.
• Regulatory and Market Risks: Botanical drug development faces unique regulatory challenges, including standardization and quality control, which may lead to delays or rejections.
• Financial Reporting and Compliance Costs: As a public company, Curanex incurs significant compliance costs and must maintain effective internal controls, which may strain resources.

• Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company focused on developing Phyto-N, a botanical drug candidate for ulcerative colitis and other indications.
• The company discontinued sales of health and dietary supplements in 2023 to focus exclusively on Phyto-N development.
• Phyto-N is in early preclinical development, with plans to complete FDA-required GLP toxicology and pharmacokinetic studies, manufacture clinical trial material, and initiate Phase I clinical trials.
• Curanex completed a GMP pilot for Phyto-N and targets IND submission for ulcerative colitis.
• The company showcased a patient case study highlighting Phyto-N's potential.
• Curanex ended Q1 2026 with $4 million in cash and plans IND submission for Phyto-N in ulcerative colitis.
• The company estimates over $150 million will be required to execute the full business plan through FDA approval and product launch.
• Curanex has no commercial products and does not generate revenue from product sales or other commercial activities.
• The company reported a net loss of approximately $3.29 million and basic and diluted EPS of -$0.12 for the quarter ended June 30, 2026.
• As of June 30, 2026, Curanex had cash and cash equivalents of about $2.94 million, current assets of approximately $4.79 million, and current liabilities of about $104,000, resulting in a current ratio of 45.95 and a cash ratio of 28.17.
• Curanex relies on third-party manufacturers for clinical drug supplies and does not have internal manufacturing capabilities.
• The company faces risks related to limited operating history, need for significant additional capital, patent protection challenges, clinical trial risks, and reliance on third parties for manufacturing and collaborations.
• Curanex filed an international PCT application to convert provisional patents related to Phyto-N into a utility patent to secure broader protection, but there is no assurance of successful patent registration.
• The company has executive employment agreements with CEO Jun Liu and COO Dr. Liqin Xie, effective March 1, 2026.
• Curanex is subject to public company reporting requirements and associated costs, estimated at over $100,000 annually.
• The company faces risks from competition, intellectual property claims, regulatory challenges specific to botanical drugs, and potential delays in clinical development.
• Curanex's business plan includes advancing Phyto-N through Phase I and Phase II clinical trials, with potential Phase III trials and eventual commercialization.
• The company may require additional financing through equity offerings, debt, strategic partnerships, or grants to fund ongoing operations and development.
• Failure to raise capital or obtain regulatory approvals could materially adversely affect the company's business and operations.